Efficacy of Apatinib plus Temozolomide in Treating Recurrent Malignant Brain Glioma
African Health Sciences · 2025
DOI: 10.4314/ahs.v25i2.17 ↗Kurz gefasst
Fachartikel in der Zeitschrift African Health Sciences, 2025. Verfasst von Guoquan Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Wuhan Jiangxia District First People's Hospital, Wuhan, China. Hauptthemen laut MEDLINE: Temozolomide, Glioma, Brain Neoplasms, Pyridines. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
To evaluate the efficacy and safety of apatinib plus tenozolomide in the treatment of recurrent malignant brain glioma.
Methods
A retrospective analysis of 108 patients with recurrent malignant brain glioma was conducted at our hospital. Out of these, 54 patients received apatinib plus tenozolomide as combination therapy (Combination group) while the remaining 54 were treated with temozolomide alone (Control group). Clinical data was collected and analyzed to compare the treatment efficacy and incidence of adverse reactions between the two groups. Additionally, patient survival and progression-free survival (PFS) were monitored and recorded.
Results
The study evaluated the efficacy of a treatment among patients who completed it. The Combination group had a higher objective response rate (ORR) and disease control rate (DCR) compared to the Control group. Treatment-related adverse reactions were mostly grade I-II and improved with symptomatic treatment. The Combination group had higher incidence rates of hypertension, proteinuria, and hand-foot syndrome. Follow-up results showed that the Combination group had a significantly better overall survival (OS) and progression-free survival (PFS) than the Control group.
Conclusion
Compared with temozolomide alone, apatinib plus tenozolomide can significantly improve the clinical efficacy in treating recurrent malignant brain glioma, prolong the survival of patients and produce tolerable adverse reactions. Keywords: Apatinib; temozolomide; recurrence; glioma; efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Wuhan Jiangxia District First People's Hospital, Wuhan, China.
Zitieren
APA
Li, G., Hu, T., Hu, Y., Shi, H., Li, L., & Xiong, G. (2025). Efficacy of Apatinib plus Temozolomide in Treating Recurrent Malignant Brain Glioma. African Health Sciences. https://doi.org/10.4314/ahs.v25i2.17
Vancouver
Li G, Hu T, Hu Y, Shi H, Li L, Xiong G. Efficacy of Apatinib plus Temozolomide in Treating Recurrent Malignant Brain Glioma. African Health Sciences. 2025. doi:10.4314/ahs.v25i2.17
BibTeX
@article{Li2025,
author = {Li, Guoquan and Hu, Tao and Hu, Yangwu and Shi, Hailiang and Li, Ling and Xiong, Gang},
title = {Efficacy of Apatinib plus Temozolomide in Treating Recurrent Malignant Brain Glioma},
journal = {African Health Sciences},
year = {2025},
doi = {10.4314/ahs.v25i2.17}
}
EUVIMED